MONMOUTH JUNCTION, N.J., Nov. 19 /PRNewswire/ -- Tris Pharma announces the appointment of industry veteran Timothy Saxon to the position of Vice President, Business Development. Tim will spearhead the company's out- licensing activities and manage the growing number of opportunities to help companies enhance their products' life cycle and competitively differentiate their products. "Tim brings with him more than 25 years of industry experience, and we believe he will be a significant asset to the company," says Ketan Mehta, CEO and Founder of Tris Pharma. "The demand for our products is rapidly increasing, and Tim is an ideal choice for leading Tris' strategic partnering both in the United States and around the world."

Prior to joining Tris Pharma, Tim served as a business development consultant in the biotech space. Previously, from 1999 to 2006, he worked for Wyeth as Assistant Vice President of Global Business Development, and conducted several significant product licensing deals in China, Japan, and elsewhere. Tim started his career as a chemical engineer, and then moved into sales and marketing for AstraZeneca (formerly ICI Pharmaceuticals). From 1991 to 1996, he worked for British-based Boots Healthcare International, first in marketing and then in business development. Tim gained his MBA from Loughborough University Business School, England, with distinction and top honors.

"The technical expertise that Tris Pharma has is remarkable," says Tim. "I feel confident and excited to engage with potential partners, knowing we can satisfy their needs and their customers' needs with our technology solutions."

About Tris Pharma:

Tris Pharma is a privately-owned product-driven specialty pharmaceutical company engaged in the research and development of innovative drug delivery technologies. The company's proprietary technologies enhance solubility and bioavailability, deliver controlled release formulations for solid and liquid dosages, offer orally disintegrating tablets for immediate and controlled release, and provide abuse deterrence platform for opiods. Through its pharma partners, Tris has more than two dozens products in development, submission and in market. Tris Pharma's research and FDA approved manufacturing facilities are located in New Jersey, USA. For more information visit http://www.TrisPharma.com.